In a report released today, Louise Chen from Cantor Fitzgerald reiterated a Buy rating on Paratek Pharmaceuticals (NASDAQ: PRTK), with a price target of $50. The company’s shares opened today at $11.05, close to its 52-week low of $10.10.
Chen noted:
“Positives from the quarter that support our thesis: 1) On 02/05/18 Paratek announced that on 02/02/18, it completed the submission of two NDAs to the U.S.”
According to TipRanks.com, Chen has 0 stars on 0-5 star ranking scale with an average return of -11.3% and a 37.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Spero Therapeutics Inc, and Theravance Biopharma.
Paratek Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $52.50.
See today’s analyst top recommended stocks >>
Based on Paratek Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $21.89 million. In comparison, last year the company had a GAAP net loss of $27.67 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Its products include Omadacycline and Sarecycline. The company was founded in February 2001 and is headquartered in Boston, MA.
